Long-term Beneficial Metabolic Effects of Adrenalectomy in Subclinical Cushing's Syndrome of Adrenal Incidentaloma

Long-term Effects of Adrenalectomy on Metabolic Syndrome, Glucose Metabolism, Lipid Metabolism, and Bone Metabolism in Subclinical Cushing's Syndrome of Adrenal Incidentaloma

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01382420

Enrollment

234

Registered

2011-06-27

Start date

2011-05-31

Completion date

2024-05-31

Last updated

2019-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cushing Syndrome

Keywords

subclinical cushing syndrome, hypercortisolism, adrenal incidentaloma, adrenalectomy

Brief summary

Objective: To determine the metabolic effects of the adrenalectomy in subclinical Cushing's syndrome of adrenal incidentaloma. Methods: 234 subclinical cushing syndrome and adrenal incidentaloma will be randomly assigned into two groups(e.g adrenalectomy group and conservative treatment group).

Interventions

PROCEDUREsurgery

adrenalectomy

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 70 Years

Healthy volunteers

Inclusion criteria

* patients with both unilateral adrenal incidentaloma and hypercortisolism * definition of hypercortisolism * overnight dexamethasone suppression test, serum cortisol\>1.8ug/dL * 24hr urine cortisol \> upper reference limit

Exclusion criteria

* patients who took medication influencing cortisol secretion * patients with definite clinical feature of cushing syndrome * moon face * abdominal striae * skin or proximal muscle atrophy * metabolic syndrome, hyperthyroidism, hyperparathyroidism, chronic renal failure, rheumatic disease, hematologic disease * patients who took following medication * insulin * oral hypoglycemic agent * thyroid hormone * anti-hyperlipidemic drug * sex hormone * patients who taking steroid hormone or who took steroid hormone more than 2 weeks within 1 year * psychiatric disease

Design outcomes

Primary

Measure	Time frame	Description
Change of lipid profile between two groups	4 Year	lipid profile with LDL,apo B

Secondary

Measure	Time frame	Description
Incidence of obesity between two groups	4Year	measurement of body weight, height

Countries

South Korea

Contacts

Primary ContactJae Hyeon Kim, M.D, Ph.D.

jaehyeonmd.kim@samsung.com82-2-3410-1580

Backup ContactSeo Young Sohn

seoyoung.sohn@samsung.com82-2-3410-1582

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026